Table 3.
Overall survival, recurrence-free survival, and recurrence by site according to pathological type
| Outcome | GIST (n=49) |
LMS (n=47) |
SRC (n=50) |
p |
|---|---|---|---|---|
| Overall survival (OS) | 0.016 | |||
| Median survival, mo | 40.6 | 42.1 | 45.5 | |
| 3-year OS, % | 72.7 | 64.3 | 67.5 | |
| 5-year OS, % | 55.3 | 48.4 | 44.9 | |
| 10-year OS, % | 52.5 | 9.2 | 23.0 | |
| Recurrence-free survival (RFS) | 0.003 | |||
| Median time to recurrence, mo | 17.8 | 7.9 | 8.8 | |
| 3-year RFS, % | 39.0 | 12.7 | 24.4 | |
| 5-year RFS, % | 35.7 | 3.4 | 21.4 | |
| Site of first recurrence, n (%) | ||||
| Liver | 20 (40.8) | 19 (40.4) | 17 (34.0) | 0.736 |
| Lung | 1 (2.0) | 17 (36.2) | 6 (12.0) | < 0.001 |
| Lymph node | 4 (8.2) | 4 (8.5) | 4 (8.0) | 0.996 |
| Peritoneum | 3 (6.1) | 1 (2.1) | 2 (4.0) | 0.615 |
| Abdominal | 5 (10.2) | 4 (8.5) | 3 (6.0) | 0.745 |
| Retroperitoneal | 1 (2.0) | 3 (6.4) | 2 (4.0) | 0.563 |
| Bone | 2 (4.1) | 3 (6.4) | 4 (8.0) | 0.718 |
| Other | 2 (4.1) | 0 | 2 (4.0) | 0.377 |
GIST: gastrointestinal stromal tumor; LMS: leiomyosarcoma; SRC: sarcoma of other or indeterminate origin.